Alzheimer’s Research
Galantamine  efficacy of galantamine in dementia and Alzheimer’s disease
  Galantamine has shown sustained benefits in patients with Alzheimer’s disease
  Galantamine  for Alzheimer’s disease
    Galantamine is a modulator at nicotinic cholinergic receptor sites potentiating cholinergic
  Galantamine  new developments in the treatment of Alzheimer’s disease
    Galantamine inhibits acetylcholinesterase and modulates nicotinic cholinergic receptors
  Galantamine  novel approach to the treatment of Alzheimer disease
    Galantamine has shown to improve cognitive function for at least 6 months
  Galantamine  a new Alzheimer drug with a past life
    Galantamine acts as both an acetylcholinesterase inhibitor and a nicotinic receptor agonist
  Galantamine  maintaining functional abilities in Alzheimer disease
    Galantamine showed evidence of functional benefit in three studies
  Galantamine  its use in Alzheimer’s
    Galantamine is an effective treatment for Alzheimer’s which improves cognition, function
  Galantamine  a new treatment for Alzheimer’s
    Galantamine produces beneficial effects even after drug treatment has been terminated
  Galantamine  benefits ‘advanced moderate’ Alzheimer’s disease for at least 12 months
  Galantamine  benefits to Alzheimer’s patients
    Galantamine was found to be significantly superior to placebo in all five studies
  Galantamine  in Alzheimer’s patients
    Galantamine slowed the decline of functional ability and cognition in Alzheimer’s disease
  Galantamine  its effects on Alzheimer’s
    Galantamine inhibits acetylcholinesterase and modulates nicotinic receptors in Alzheimer’s
  Galantamine  a study in Alzheimer’s
    Galantamine 16 and 24 mg/day significantly benefits the cognitive, functional, and behavioral symptoms of Alzheimer’s disease as compared with placebo
  Galantamine  a six month Alzheimer’s study
    Galantamine is effective and safe in Alzheimer’s disease. At 6 months, galantamine significantly improved cognition and cognitive and daily function were maintained for 12 months
  Galantamine  profiles of current therapies for Alzheimer’s
    Galantamine differs from other AChEIs in that it has allosteric modulating activity at nicotinic
  Galantamine  dual mode of action for Alzheimer’s
  Galantamine  economic analysis of galantamine in Alzheimer’s treatment
  Galantamine  cost of Alzheimer’s treatment
  Galantamine  provides broad benefits for Alzheimer’s for up to six months
  Galantamine  the rationale for treating vascular dementia with galantamine
    There is evidence that the central cholinergic system is impaired in vascular dementia
  Galantamine  ameliorates early signs of neurodegeneration
Memory And Cognition

Galantamine  effect on memory & nicotinic receptors
  Effects of galantamine on memory and nicotinic receptors in old rats
  Galantamine  maintaining cognitive function in Alzheimer disease
    Galantamine inhibits AChE and modulates cholinergic nicotinic receptors
  Galantamine  therapeutic effects beyond cognition
    Galantamine-treated patients had a significantly better outcome than placebo-treated patients, and after 12 months of treatment, patients’ functional ability was preserved
Safety and Efficacy
Cholinesterase inhibitors
Galantamine  acetylcholinesterase inhibition
  Evidence suggests galantamine to be similar to other acetylcholinesterase inhibitors in improving cognitive function in Alzheimer’s disease patients
  Galantamine  switching cholinesterase inhibitors in patients with Alzheimer’s
Nicotinic receptors
Galantamine  nicotinic receptors in Alzheimer’s
  Galantamine maintains patients’ level of cognitive and daily function for at least 1 year, which has not been reported for other acetylcholinesterase inhibitors
  Galantamine  effect on nicotinic receptor binding
    Galantamine can increase the density of nicotinic receptors in brain regions that are involved in learning and memory. This may underlie the cognitive benefits produced by Galantamine in Alzheimer’s
  Galantamine  nicotinic modulation in older rabbits
    Galantamine may be effective as a cognition-enhancer in Alzheimer’s disease
  Galantamine  sensitizes nicotinic receptors
  Galantamine  nicotinic receptors, galantamine and Alzheimer’s
Misc research
Galantamine  switching previous therapies for Alzheimer’s disease to galantamine
  Acetylcholinesterase inhibitors are the most frequently prescribed drugs for the treatment of Alzheimer’s
  Galantamine  Determining the optimal conditions for switching patients from donepezil to galantamine
  Galantamine  rationale for switching from donepezil to galantamine
    Galantamine is an attractive option for patients with Alzheimer’s disease who have not benefited from their current therapy. Methods for switching patients from donepezil or rivastigmine to Galantamine are needed
  Galantamine  facilitates synaptic transmission in the central nervous system
    Galantamine, a cholinesterase inhibitor and a nicotinic allosteric potentiating ligand used
  Galantamine  an allosterically potentiating ligand
    Galantamine is a novel drug treatment for mild to moderate Alzheimer’s disease